Intellia Therapeutics Inc. (NTLA)
Market Closed
3 Jun, 20:00
$
13. 02
-0.11
-0.8378%
Pre Market
$
+0.1 +0.768% 13. 12
1.47B Market Cap
- P/E Ratio
- Div Yield
3.02M Volume
-5.42 Eps
$ 13.13
Previous Close Investors:
Want to track NTLA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Wood added to her positions in Reddit, Intellia Therapeutics, and PagerDuty on Wednesday. Wood's Ark Invest was a buyer of Reddit the day it went public in March.
Fool | 1 year ago
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
Seekingalpha | 1 year ago
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Zacks | 1 year ago
